Search

Displaying results 421 - 430 of 4600 in total
  1. Drug

    Casirivimab

    go.drugbank.com/drugs/DB15941
    ApprovedInvestigational

    [L23524] In November 2021, the same indication was approved by the EMA. … [A221495] On November 21 2020, the FDA authorized emergency approval of REGEN-COV2 to treat mild to moderate COVID-19 in patients aged 12 years and older.

  2. Drug

    Somapacitan

    go.drugbank.com/drugs/DB15093
    ApprovedInvestigational

    [A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily.

  3. Drug

    Atogepant

    go.drugbank.com/drugs/DB16098
    ApprovedInvestigational

    [L38814] While its approval was predated by two other members of the same drug family, namely [ubrogepant] and [rimegepant], these agents are indicated only for abortive migraine therapy - atogepant is … It was developed by AbbVie and received FDA approval under the brand name Qulipta in September 2021.

  4. Drug

    Odevixibat

    go.drugbank.com/drugs/DB16261
    ApprovedInvestigational

    Odevixibat, or A4250, is an ileal sodium/bile acid cotransporter inhibitor indicated for the treatment of pruritus in patients older than 3 months, with progressive familial intrahepatic cholestasis (PFIC

  5. Drug

    Birch bark extract

    go.drugbank.com/drugs/DB16536
    ApprovedInvestigational

    [L42390] Filsuvez was subsequently approved for the same indication by the US FDA in December 2023. … [L50031] The EMA marketing authorization for Episalvan[L42370] was withdrawn by the manufacturer in 2022.

  6. Drug

    Lovotibeglogene autotemcel

    go.drugbank.com/drugs/DB18680
    ApprovedInvestigational

    to be approved by the FDA. … [A262736,L49256] On December 8, 2023, lovotibeglogene autotemcel was approved by the FDA under the brand name Lyfgenia for the treatment of sickle cell disease (SCD) in patients ages 12 and older who

  7. Drug

    Potassium bicarbonate

    go.drugbank.com/drugs/DB11098
    ApprovedInvestigational

    [T141] It is registered in the FDA under the section of suitable, safe and effective ingredients for OTC antacids.[L1836] This FDA denomination classifies potassium bicarbonate as a GRAS ingredient. … It is produced by the passage of carbon dioxide through an aqueous potassium carbonate solution. It is used in medicine as an antacid.

    Mixtures: Neo K, POT-K 1,56 G EFERVESAN TABLET, 60 ADETProducts: K-effervescent, Effer-K Orange
  8. Drug

    Omega-3 fatty acids

    go.drugbank.com/drugs/DB11133
    ApprovedInvestigationalNutraceutical

    α-linolenic acid (ALA) (found in plant oils), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) (both commonly found in fish oil that originally come from microalgae that is further consumed by

    Mixtures: K-OMEGASQUA (Softgel)
  9. Drug

    Zinc sulfate

    go.drugbank.com/drugs/DB09322
    ApprovedInvestigational

    Zinc sulfate is the inorganic compound with the formula ZnSO4 and historically known as "white vitriol". It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic heal...

    Mixtures: Clear Eyes Acr By Murine, Z-FULL MK TABLETAS
  10. Drug

    Gemtuzumab ozogamicin

    go.drugbank.com/drugs/DB00056
    ApprovedInvestigational

    Marketing approval of gemtuzumab ozogamicin was granted on May 17, 2000 by FDA as a treatment for patients with CD33-positive AML in first relapse who are 60 years of age or older and who are not considered … On September 1 2017, gemtuzumab ozogamicin was again approved for the treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia but with a lower dosing regimen and a different schedule